These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 3638137)

  • 1. In vitro inhibition of the classical pathway of human complement by a natural microbial product, colistin sulphate.
    Asghar SS; de Koster A; van der Helm HJ
    Biochem Pharmacol; 1986 Sep; 35(17):2917-21. PubMed ID: 3638137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro inhibition of the classical pathway of human complement by polymyxin B.
    Asghar SS; Boot T; van der Helm HJ
    Biochem Pharmacol; 1987 Sep; 36(18):2927-30. PubMed ID: 2820426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eosinophil granule major basic protein regulates generation of classical and alternative-amplification pathway C3 convertases in vitro.
    Weiler JM; Gleich GJ
    J Immunol; 1988 Mar; 140(5):1605-10. PubMed ID: 3346544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of complement by a series of substituted 2-aryl-1,3-indandiones: interaction with the fifth component of complement.
    Asghar SS; Siddiqui AH; van der Goot H; Timmerman H
    Mol Immunol; 1986 May; 23(5):459-65. PubMed ID: 3748011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a streptococcal preparation on the complement system.
    Kato H; Yokoe N; Matsumura N; Nishida K; Ikezaki M; Hosokawa K; Hotta T; Takemura S; Yoshikawa T; Kondo M
    Jpn J Exp Med; 1979 Oct; 49(5):343-50. PubMed ID: 529490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro inhibition of the classical and alternate pathways of activation of human complement by N acetyl aspartyl glutamic acid (NAAGA).
    Etievant M; Leluc B; David B
    Agents Actions; 1988 Jun; 24(1-2):137-44. PubMed ID: 3261498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cleavage of the third component of human complement (C3) by its small cleavage fragment, C3a: inhibition occurs with the classical-pathway, but not the alternative-pathway, C3 convertase.
    Strunk RC; Webster RO
    Mol Immunol; 1985 Jan; 22(1):37-43. PubMed ID: 3871899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of in vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA).
    Feuillard J; Maillet F; Goldschmidt P; Weiss L; Kazatchkine MD
    Agents Actions; 1991 Mar; 32(3-4):343-6. PubMed ID: 1862751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface-dependent modulation by H of C5 cleavage by the cell-bound alternative pathway C5 convertase of human complement.
    Fischer E; Kazatchkine MD
    J Immunol; 1983 Jun; 130(6):2821-4. PubMed ID: 6222117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of immune haemolysis by a serum factor found in C3-deficient subjects.
    Kitamura H; Tsuboi M
    Immunology; 1989 Feb; 66(2):264-9. PubMed ID: 2925225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of classical C5 convertase in the complement system by factor H.
    Ito S; Tamura N
    Immunology; 1983 Dec; 50(4):631-5. PubMed ID: 6228516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-complement activity of oleanolic acid: an inhibitor of C3-convertase of the classical complement pathway.
    Kapil A; Sharma S
    J Pharm Pharmacol; 1994 Nov; 46(11):922-3. PubMed ID: 7897600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New methods for the preparation of the cellular intermediate EAC14.
    Asghar SS; Out J
    J Immunol Methods; 1986 Dec; 95(2):277-81. PubMed ID: 3794347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple effects of a diamidine (propamidine) on complement activation.
    Vogt W; Hinsch B; Schmidt G; Von Zabern I
    Immunology; 1979 Jan; 36(1):131-7. PubMed ID: 422224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C3-independent immune haemolysis: mechanism of membrane attack complex formation.
    Kitamura H; Tsuboi M; Nagaki K
    Immunology; 1986 Sep; 59(1):147-51. PubMed ID: 3759127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the classical and alternative pathways of human and guinea pig complement by pyran copolymer.
    Webster GF; McArthur WP
    Int Arch Allergy Appl Immunol; 1981; 66(3):304-9. PubMed ID: 6913544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An anticomplementary agent, K-76 monocarboxylic acid: its site and mechanism of inhibition of the complement activation cascade.
    Hong K; Kinoshita T; Miyazaki W; Izawa T; Inoue K
    J Immunol; 1979 Jun; 122(6):2418-23. PubMed ID: 448130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C3 nephritic factor stabilization of the classic C3 convertase: a role for C2 in C3 nephritic factor activity.
    McLean RH; Nilson SH
    Proc Soc Exp Biol Med; 1979 Jul; 161(3):358-63. PubMed ID: 461464
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.